Literature DB >> 11435052

A small dose of midazolam decreases the time to achieve hypnosis without delaying emergence during short-term propofol anesthesia.

Y U Adachi1, K Watanabe, H Higuchi, T Satoh.   

Abstract

STUDY
OBJECTIVE: To evaluate the effect of a small dose of midazolam (10 microg kg(-1)) on induction and emergence during short-term propofol anesthesia and to investigate the effects of subsequent administration of flumazenil.
DESIGN: Double-blinded, prospective, randomized study.
SETTING: Operating room of a medical college hospital. PATIENTS: 30 male ASA physical status I and II patients (ages 51 to 75) scheduled for minor surgery under spinal anesthesia.
INTERVENTIONS: Patients were randomly allocated to one of three groups: the placebo-propofol-placebo (PP) group, the midazolam-propofol-placebo (MP) group, or the midazolam-propofol-flumazenil (MF) group. After administering placebo or midazolam (10 microg kg(-1)), propofol 250 microg kg(-1) min(-1) was infused. Immediately after confirming that the patient was hypnotized, we terminated the propofol infusion and administered placebo or flumazenil (5 microg kg(-1)). MEASUREMENTS: The dose and the times required to achieve hypnosis (the first endpoint) and to emerge from anesthesia (the second endpoint). The plasma concentration at each endpoint was determined. MAIN
RESULTS: Midazolam significantly decreased the dose and time needed to achieve hypnosis [PP vs. MP, 66 +/- 14 vs. 48 +/- 15 mg, 260 +/- 55 vs. 179 +/- 44 sec, respectively (mean +/- SD)]. Thus, the plasma concentration of propofol at hypnosis was significantly lower (PP vs. MP, 3.31 +/- 0.78 vs. 2.41 +/- 0.57 microg mL(-1)). The time to emerge from anesthesia was not prolonged by midazolam, and was further shortened by administration of flumazenil (PP, MP vs. MF, 237 +/- 77, 207 +/- 71 s vs. 126 +/- 56 sec, respectively). Flumazenil also reversed the reduction in propofol concentration induced by midazolam at emergence (PP, MP, and MF, 0.54 +/- 0.17, 0.37 +/- 0.15, and 0.59 +/- 0.22 microg mL(-1), respectively).
CONCLUSIONS: Coadministration of 10 microg kg(-1)midazolam decreases the dose and time required to achieve hypnosis with propofol induction without delaying emergence from anesthesia. Additional administration of flumazenil further shortens the time to emerge from midazolam-propofol anesthesia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435052     DOI: 10.1016/s0952-8180(01)00265-3

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  6 in total

1.  Dexmedetomidine and hydroxyzine synergistically potentiate the hypnotic activity of propofol in mice.

Authors:  Kaori Kimura-Kuroiwa; Yushi U Adachi; Yukako Obata; Mikito Kawamata; Shigehito Sato; Naoyuki Matsuda
Journal:  J Anesth       Date:  2012-02-18       Impact factor: 2.078

2.  A comparative study of propofol alone and propofol combined with midazolam for dental treatments in special needs patients.

Authors:  I-Hsin Lin; Mao-Suan Huang; Pei-Yu Wang; Ta-Sen Huang; See-Yen Chong; Sam Li-Sheng Chen; Hung-Huey Tsai
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

3.  The determinants of propofol induction time in anesthesia.

Authors:  Yushi U Adachi; Maiko Satomoto; Hideyuki Higuchi; Kazuhiko Watanabe
Journal:  Korean J Anesthesiol       Date:  2013-08-27

4.  JM-1232(-) and propofol, a new combination of hypnotics with short-acting and non-cumulative preferable properties.

Authors:  Saori Taharabaru; Takahiro Tamura; Michiko Higashi; Naoyuki Matsuda; Maiko Satomoto; Yushi U Adachi; Aiji Boku Sato; Masahiro Okuda
Journal:  Exp Anim       Date:  2020-10-16

5.  Clinical efficacy of high-flow nasal oxygen in patients undergoing ERCP under sedation.

Authors:  Boram Cha; Man-Jong Lee; Jin-Seok Park; Seok Jeong; Don Haeng Lee; Tae Gyu Park
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

6.  Combined sedation with midazolam/propofol for gastrointestinal endoscopy in elderly patients.

Authors:  Astrid Kerker; Christian Hardt; Hans-Eugen Schlief; Franz Ludwig Dumoulin
Journal:  BMC Gastroenterol       Date:  2010-01-27       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.